TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17874823

Group type: EXPERIMENTAL
Intervention: P40 tablets (2250 mg/d, 900 mg/d of CoQ10) for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15541675

Group type: EXPERIMENTAL
Intervention: ProDisc II
Number of subjects: 78

Group type: COMPARATOR
Intervention: 360-degree lumbar spinal fusion
Number of subjects: 78
Study: 11277606

Group type: EXPERIMENTAL
Intervention: 0.25 mg/70 kg triazolam, ingested orally 30 min before bedtime
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo, ingested orally 30 min before bedtime
Number of subjects: 11

Group type: COMPARATOR
Intervention: Random choice between triazolam and placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-sleep questionnaires
Number of subjects: 11
Study: 9775243

Group type: EXPERIMENTAL
Intervention: Syringing with retropunctal cautery (RPC) and one-snip punctoplasty (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Syringing alone (group A)
Number of subjects: 30
Study: 7843192

Group type: EXPERIMENTAL
Intervention: 100 micrograms EE/day (n = 11)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 300 micrograms EE/day (n = 25)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 500 micrograms EE/day (n = 16)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Untreated group A (n = 21)
Number of subjects: 52
Study: 3339140

Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir five times a day for 5 days, then 400 mg three times a day for 1 or 2 months, followed by 400 mg twice a day thereafter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 mg oral acyclovir five or six times a day for 5 to 10 days
Number of subjects: 0
Study: 29294497

Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CSD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No closed suction drainage (nondrainage)
Number of subjects: 36
Study: 27311484

Group type: EXPERIMENTAL
Intervention: Ectopic expression of K+CN11 in HEK+293T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disruption of the K+CN11 gene or mutation of key residues for K++ permeability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutant cells with disrupted K+CN11
Number of subjects: 0
Study: 25640151

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT), n = 76
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT), n = 75
Number of subjects: 182

Group type: COMPARATOR
Intervention: Waiting List Control (WLC), n = 31
Number of subjects: 182
Study: 23266840

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 2118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2118
Study: 21917633

Group type: EXPERIMENTAL
Intervention: Hyperglycemia in type 2 diabetic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperglycemia in controls
Number of subjects: 0
Study: 17524398

Group type: EXPERIMENTAL
Intervention: Group A: M199 + 20% fetal bovine serum (FBS) + 75 mIU/mL recombinant follicle‐stimulating hormone (FSH) + 0.5 IU/mL recombinant hCG
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Group B: hCG-free IVM medium (M199 + 20% FBS + 75 mIU/mL recombinant FSH) for 10 hours, then transferred to Group A medium
Number of subjects: 62

Group type: COMPARATOR
Intervention: Group C: hCG-free IVM medium only
Number of subjects: 62
Study: 15842516

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) injected immediately before a meal (0.15 U/kg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Regular human insulin (HI) injected 30 min before a meal (0.15 U/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 37
Study: 12204014

Group type: EXPERIMENTAL
Intervention: Doxazosin (2 to 8 mg/d)
Number of subjects: 24317

Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 to 25 mg/d)
Number of subjects: 24317

Group type: EXPERIMENTAL
Intervention: Overall (after adjustment for follow-up systolic/diastolic blood pressure)
Number of subjects: 24317
Study: 10328637

Group type: EXPERIMENTAL
Intervention: Reiki plus Reiki
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reiki plus placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus Reiki
Number of subjects: 20
Study: 7481082

Group type: EXPERIMENTAL
Intervention: Full vision condition
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ambient vision condition
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: No vision condition
Number of subjects: 26

Group type: COMPARATOR
Intervention: Skilled lifters across all vision conditions
Number of subjects: 26
Study: 1946267

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study: 7128665

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 66 mg noscapine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral 150 mg noscapine (rapidly dissolving tablets)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral 150 mg noscapine (ion exchange resin-bound tablet)
Number of subjects: 5
Study: 28902067

Group type: EXPERIMENTAL
Intervention: Targeted prevention program
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Combined prevention program
Number of subjects: 1353
Study: 26682500

Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin and 500 mg metformin XR FDC
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin and 1000 mg metformin XR FDC
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (individual components of dapagliflozin and metformin XR)
Number of subjects: 129
Study: 25575802

Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP)
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 2782
Study: 22038376

Group type: EXPERIMENTAL
Intervention: MDPC Web site resources
Number of subjects: 3478

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire‐9 (PHQ‐9)
Number of subjects: 3478
Study: 20524710

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no CGA)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CGA by study physicians
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CGA initiated drugs
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Drugs terminated by study physicians
Number of subjects: 1000
Study: 18719936

Group type: EXPERIMENTAL
Intervention: Bed rest with resistive vibration exercise (BR-RVE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bed rest (BR-Ctrl)
Number of subjects: 16
Study: 16671160

Group type: EXPERIMENTAL
Intervention: Frontotemporal Dementia (FTD)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Semantic Dementia (SD)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Alzheimer-type Dementia (AD)
Number of subjects: 74
Study: 12792162

Group type: EXPERIMENTAL
Intervention: Low serum albumin levels
Number of subjects: 2771

Group type: EXPERIMENTAL
Intervention: Confusion
Number of subjects: 2771

Group type: EXPERIMENTAL
Intervention: Fecal incontinence
Number of subjects: 2771

Group type: EXPERIMENTAL
Intervention: Do Not Resuscitate (DNR) order
Number of subjects: 2771

Group type: EXPERIMENTAL
Intervention: Malnourished status
Number of subjects: 2771

Group type: EXPERIMENTAL
Intervention: Urinary catheter requirement
Number of subjects: 2771
Study: 10916803

Group type: EXPERIMENTAL
Intervention: Active antihypertensive therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-therapeutic control
Number of subjects: 13
Study: 8974553

Group type: EXPERIMENTAL
Intervention: Program to improve recording of drug prescribing
Number of subjects: 463
Study: 8460608

Group type: EXPERIMENTAL
Intervention: 17% olive oil plus 3% soybean oil emulsion
Number of subjects: 6

Group type: COMPARATOR
Intervention: 20% soybean oil emulsion
Number of subjects: 6
Study: 3884916

Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospice care for significant others (SOs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control SOs
Number of subjects: 0
Study: 30810481

Group type: EXPERIMENTAL
Intervention: Two-layer wound sealing (waterproof topical dressing as first layer and antimicrobial drape as second layer)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (uninjured hand)
Number of subjects: 20
Study: 29340913

Group type: EXPERIMENTAL
Intervention: Skills TO Manage Pain (STOMP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study: 27000329

Group type: EXPERIMENTAL
Intervention: Prospective memory intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 24553022

Group type: EXPERIMENTAL
Intervention: Bupivacaine (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine + Sufentanil (7.5 mg + 5 μg)
Number of subjects: 40
Study: 22951783

Group type: EXPERIMENTAL
Intervention: Russian β-interferon-1b bioanalogue (infibeta)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 20534124

Group type: EXPERIMENTAL
Intervention: 4000 IU/week of intravenous epoietin alfa or beta (or equivalent ESA)
Number of subjects: 2204

Group type: COMPARATOR
Intervention: 18000 IU/week of intravenous epoietin alfa or beta (or equivalent ESA)
Number of subjects: 2204

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 2204

Group type: EXPERIMENTAL
Intervention: Cost assessment
Number of subjects: 2204
Study: 18398651

Group type: EXPERIMENTAL
Intervention: Toupet 1.5-cm wrap
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Toupet 3-cm wrap
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Nissen 1.5-cm wrap
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Nissen 3-cm wrap
Number of subjects: 153
Study: 15865094

Group type: EXPERIMENTAL
Intervention: 5-FU/PSK therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 87
Study: 14646711

Group type: EXPERIMENTAL
Intervention: Metal-on-metal bearings for total hip arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional metal-on-polyethylene bearings
Number of subjects: 0
Study: 10373231

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg/d)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 to 20 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 47
Study: 8675100

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate 500 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate 1000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate 1500 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate (highest dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate
Number of subjects: 0
Study: 1378114

Group type: EXPERIMENTAL
Intervention: 25 mg bemetizide (n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 25 mg bemetizide plus 50 mg triamterene (n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mg bemetizide (n = 16)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mg bemetizide plus 20 mg triamterene (n = 16)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: bemetizide group
Number of subjects: 36
Study: 3904390

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30309256

Group type: EXPERIMENTAL
Intervention: Aquatic window mural
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tree window mural
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 90
Study: 29485746

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT)
Number of subjects: 2448
Study: 26271367

Group type: EXPERIMENTAL
Intervention: Preoperative state anxiety measured using the State‐Trait Anxiety Inventory
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Independent predictors of postoperative delirium
Number of subjects: 86
Study: 24781721

Group type: EXPERIMENTAL
Intervention: Health education (active management and postural hygiene) combined with lumbar strengthening exercise
Number of subjects: 49

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 49
Study: 19895595

Group type: EXPERIMENTAL
Intervention: Oral enteral nutrition supplement plus supplemental parenteral nutrition (PN+)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral enteral nutrition supplement (PN-)
Number of subjects: 82
Study: 16274150

Group type: EXPERIMENTAL
Intervention: Early placement of single-tooth acid-etched Osseotite implant (average of 10 days after extraction)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delayed placement of single-tooth acid-etched Osseotite implant (average of 3 months after extraction)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Early placement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delayed placement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 12066728

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg tds for 24 h before and 48 h after surgery
Number of subjects: 30
Study: 9563808

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-focused treatment
Number of subjects: 54
Study: 7922829

Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 71
Study: 3409309

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 32
Study: 11377126

Group type: EXPERIMENTAL
Intervention: Donation promise letter
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard covering letter
Number of subjects: 219
Study: 30707709

Group type: EXPERIMENTAL
Intervention: Patient Transfer Decision Difficulty Scale (PTDDS)
Number of subjects: 2
Study: 30242221

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 24
Study: 27442346

Group type: EXPERIMENTAL
Intervention: POLST (experimental)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no POLST)
Number of subjects: 0
Study: 24960395

Group type: EXPERIMENTAL
Intervention: NuSmile crowns
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Kinder Krowns
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both crown types
Number of subjects: 14
Study: 22734802

Group type: EXPERIMENTAL
Intervention: Hartcoach‐programme plus usual care
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 20459818

Group type: EXPERIMENTAL
Intervention: Prolapse surgery combined with anti-incontinence surgery (concomitant surgery)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Prolapse surgery only
Number of subjects: 450
Study: 17684102

Group type: EXPERIMENTAL
Intervention: 12-h fast
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 48-h fast
Number of subjects: 25
Study: 15241751

Group type: EXPERIMENTAL
Intervention: 90, 180, or 360U of BTX
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 11755938

Group type: EXPERIMENTAL
Intervention: Meals rich in heated safflower oil (60 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Meals rich in heated olive oil (60 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Meals containing unheated safflower oil (US)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Meals containing unheated olive oil (UO)
Number of subjects: 16
Study: 9640058

Group type: EXPERIMENTAL
Intervention: Pentoxifylline treatment (1200 mg i.v. for the first 5 days, followed by 800 mg orally for subsequent days for 30 days)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Typical treatment
Number of subjects: 107
Study: 8207318

Group type: EXPERIMENTAL
Intervention: Insulin (100 U/ml) in sterile saline administered twice daily for 8 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (sterile saline) administered twice daily for 8 weeks
Number of subjects: 8
Study: 2492464

Group type: EXPERIMENTAL
Intervention: Small inspiratory resistive load R1 (2.5 cmH2O L/s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small inspiratory resistive load R2 (5.2 cmH2O L/s)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unloaded breathing (R0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy nonsmokers (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General testing conditions
Number of subjects: 0
Study: 1153996

Group type: EXPERIMENTAL
Intervention: Drugs that presumably improve the clearance of diseased airways
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31722294

Group type: EXPERIMENTAL
Intervention: Custom-made daily routine (CDR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Home-based exercise (HE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study: 28225450

Group type: EXPERIMENTAL
Intervention: Small incentives for attending timely clinic visits or achieving high medication adherence (US $1.50 awarded through a drawing).
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group received the usual standard of care.
Number of subjects: 155
Study: 25522762

Group type: EXPERIMENTAL
Intervention: Intervention 1 and standard care (n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intervention 2 and standard care (n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care alone (n=30)
Number of subjects: 90
Study: 24027944

Group type: EXPERIMENTAL
Intervention: Gestures conveying accurate information about the scene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gestures conveying false, misleading information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live interview with misleading gestures
Number of subjects: 0
Study: 21483401

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 600 mg or 1200 mg daily for 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 18649369

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: midazolam and propofol
Number of subjects: 0
Study: 16445786

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate gel
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate lotion
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: BP/erythromycin gel
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Erythromycin/zinc solution
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall satisfaction ranking
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 67
Study: 14740155

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (0.375% Bupivacaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraarticular local anaesthetic injection (Bupivacaine)
Number of subjects: 50
Study: 11014397

Group type: EXPERIMENTAL
Intervention: Group-format self-care intervention
Number of subjects: 1448
Study: 9349159

Group type: EXPERIMENTAL
Intervention: 5 mm beam diameter (26 micrograms, n = 10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6 mm beam diameter (42 micrograms, n = 10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5 mm beam diameter (62 micrograms, n = 10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6 mm beam diameter (78 micrograms, n = 10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: multizone treatment (62 micrograms, n = 10)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 50
Study: 8315258

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3713102

Group type: EXPERIMENTAL
Intervention: Chronic beta-receptor blockade
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated control study
Number of subjects: 11
Study: 30150567

Group type: EXPERIMENTAL
Intervention: LTE mobile phone EMF exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 0
Study: 27042334

Group type: EXPERIMENTAL
Intervention: Patient-initiated appointments
Number of subjects: 131
Study: 24571603

Group type: EXPERIMENTAL
Intervention: Auricular acupressure therapy (AAT) for 4 weeks
Number of subjects: 22
Study: 22717890

Group type: EXPERIMENTAL
Intervention: Carbetocin 80-120 μg
Number of subjects: 80
Study: 20484124

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Structured Diabetes Education (SDE)
Number of subjects: 44
Study: 18772643

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and hydrochlorothiazide 25 mg (T80/H25)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Telmisartan 80 mg and hydrochlorothiazide 12.5 mg (T80/H12.5)
Number of subjects: 713
Study: 16033295

Group type: EXPERIMENTAL
Intervention: Intravitreous pegaptanib 0.3 mg
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Intravitreous pegaptanib 0.3-3 mg
Number of subjects: 1208
Study: 12023168

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low energy diet
Number of subjects: 82